A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer

Ki vehet részt

• Female participants with inoperable locally advanced or metastatic breast cancer
• Confirmed diagnosis of HR-positive/HER2-negative breast cancer
• Postmenopausal woman
• Previously untreated with any systemic anticancer therapy for their locoregionally recurrent or metastatic HR-positive disease. Participants may have received cytotoxic chemotherapy within (neo) adjuvant previous treatment of breast cancer but must show progressive disease prior to enrollment
• Have either measurable disease or non-measurable bone-only disease
• ECOG performance status 0-2
• Adequate organ and marrow function
• Resolution of all acute toxic effects of prior anticancer therapy or surgical procedures to NCI Common Terminology Criteria for Adverse Events (CTCAE) version 6.0 Grade ≤ 1 (except alopecia or other toxicities not considered a safety risk for the participant at the investigator's discretion)
• BMI ≥ 19 and ≤ 39 kg/m2

Ki nem vehet részt

• Concurrent malignancy or malignancy within 3 years of randomization, with the exception of adequately treated basal or squamous cell carcinoma, non-melanomatous skin cancer, or curatively resected cervical cancer
• Major surgery, chemotherapy, radiotherapy, any investigational agents, or other anticancer therapy within 14 days (2 weeks) before randomization. Participants who received prior radiotherapy to > 25% of bone marrow are not eligible independent of when it was received
• Bisphosphonates or receptor activator of nuclear factor kappa-β ligand (RANKL) inhibitors initiated or have their dose changed within 14 days prior to randomization, i.e., participants should be on stable dose treatment for at least 14 days prior to randomization
• Use of the following medications within the 3 previous days or a period of 5 half-lives, (whichever is longer) prior to randomization:; Any medications or products including St. John's wort, known to be strong inducers of CYP3A; Any medications or products known to be strong inhibitors of CYP3A (e.g., grapefruit or grapefruit juice); Any medications known to be inducers of CYP2A6; Any medications known to be inhibitors of CYP2A6
• Concurrently use of other anticancer therapy
• Participants with inflammatory breast cancer
• Active cardiac disease or documented history of cardiac dysfunction
• Uncontrolled hypertension
• History of symptomatic vertebral fragility fracture or any fragility fracture of the hip, pelvis, wrist, or other location (defined as any fracture without a history of trauma or because of a fall from standing height or less, excluding fingers, toes, face and skull)
• Presence of medical conditions associated with low bone mass
• History of ILD/pneumonitis
• Presence of detectable viral infection, including HBV, HCV, and HIV. Screening is not required for enrollment. Note: Participants who have been effectively treated and have a sustained virologic response are eligible for enrollment
• Other severe acute or chronic medical or psychiatric condition, including recent or active suicidal ideation/behavior, or laboratory or ECG abnormalities that may increase the risk associated with study participation or study intervention administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study
• Hormonal medications or medications or products known to affect serum LH, FSH (except spironolactone which is allowed if medically indicated), or estrogen/E2 levels within 3 months prior to randomization. This includes, but is not limited to, estrogen or progesterone hormone replacement therapy, oral contraceptives, androgens, LHRH analogs, prolactin inhibitors, or antiandrogens and other medications, herbal remedies, and/or supplements for the treatment of vasomotor hot flush symptoms administered via any route, including topical or intravaginal administration
• Participants with advanced, symptomatic, visceral spread who are at risk of life-threatening complications in the short term
• Known uncontrolled or symptomatic central nervous system (CNS) metastases